Efficacy and Safety of Peginterferon Alfa-2a (40KD) Plus Ribavirin in Hepatitis C Patients with Advanced Fibrosis and Cirrhosis
Identifieur interne : 007905 ( Main/Exploration ); précédent : 007904; suivant : 007906Efficacy and Safety of Peginterferon Alfa-2a (40KD) Plus Ribavirin in Hepatitis C Patients with Advanced Fibrosis and Cirrhosis
Auteurs : Savino Bruno [Italie] ; Mitchell L. Shiffman [États-Unis] ; Stuart K. Roberts [Australie] ; Edward J. Gane [Nouvelle-Zélande] ; Diethelm Messinger [Allemagne] ; Stephanos J. Hadziyannis [Grèce] ; Patrick Marcellin [France]Source :
- Hepatology : (Baltimore, Md.) [ 0270-9139 ] ; 2010.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
Abstract
The objective of this study is to determine the efficacy and safety of peginterferon alfa-2a (40KD)/ribavirin in patients with advanced fibrosis. Data from 341 genotype 1/4 patients (99 with bridging fibrosis/cirrhosis) treated for 48 weeks and 1547 genotype 2/3 patients (380 with bridging fibrosis/cirrhosis) treated for 16 or 24 weeks enrolled in three randomized international studies were analyzed. Sustained virological response (SVR) rates decreased progressively from 60% in genotype 1/4 patients without advanced fibrosis to 51% in those with bridging fibrosis and 33% in those with cirrhosis (trend test P = 0.0028); and from 76% to 61% and 57%, respectively, in genotype 2/3 patients treated for 24 weeks (trend test P < 0.0001). Irrespective of genotype, patients without advanced fibrosis were more likely to have an earlier response to treatment that was associated with higher SVR rates and lower relapse rates during untreated follow-up. Among patients with or without a diagnosis of advanced fibrosis, rates of SVR and relapse were similar for patients with similar responses in the first 12 weeks. Conclusion: Compared with patients with less severe disease, SVR rates are significantly lower in patients with advanced fibrosis. However, irrespective of genotype and degree of fibrosis, the time to become hepatitis C virus (HCV) RNA undetectable was the strongest predictor of SVR.
Affiliations:
- Allemagne, Australie, France, Grèce, Italie, Nouvelle-Zélande, États-Unis
- Attique (région), Bade-Wurtemberg, District de Karlsruhe, Lombardie, Victoria (État)
- Athènes, Mannheim, Melbourne, Milan
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 002823
- to stream PascalFrancis, to step Curation: 003763
- to stream PascalFrancis, to step Checkpoint: 002455
- to stream Main, to step Merge: 007F23
- to stream Main, to step Curation: 007905
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Efficacy and Safety of Peginterferon Alfa-2a (40KD) Plus Ribavirin in Hepatitis C Patients with Advanced Fibrosis and Cirrhosis</title><author><name sortKey="Bruno, Savino" sort="Bruno, Savino" uniqKey="Bruno S" first="Savino" last="Bruno">Savino Bruno</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>AO Fatebenefratelli e Oftalmico</s1><s2>Milan</s2><s3>ITA</s3><sZ>1 aut.</sZ></inist:fA14><country>Italie</country><placeName><settlement type="city">Milan</settlement><region nuts="2">Lombardie</region></placeName></affiliation></author><author><name sortKey="Shiffman, Mitchell L" sort="Shiffman, Mitchell L" uniqKey="Shiffman M" first="Mitchell L." last="Shiffman">Mitchell L. Shiffman</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Virginia Commonwealth University Medical Center</s1><s2>Blacksburg, VA</s2><s3>USA</s3><sZ>2 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Virginia Commonwealth University Medical Center</wicri:noRegion></affiliation></author><author><name sortKey="Roberts, Stuart K" sort="Roberts, Stuart K" uniqKey="Roberts S" first="Stuart K." last="Roberts">Stuart K. Roberts</name><affiliation wicri:level="3"><inist:fA14 i1="03"><s1>The Alfred Hospital</s1><s2>Melbourne</s2><s3>AUS</s3><sZ>3 aut.</sZ></inist:fA14><country>Australie</country><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Gane, Edward J" sort="Gane, Edward J" uniqKey="Gane E" first="Edward J." last="Gane">Edward J. Gane</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Auckland Clinical Studies</s1><s2>Auckland</s2><s3>NZL</s3><sZ>4 aut.</sZ></inist:fA14><country>Nouvelle-Zélande</country><wicri:noRegion>Auckland Clinical Studies</wicri:noRegion></affiliation></author><author><name sortKey="Messinger, Diethelm" sort="Messinger, Diethelm" uniqKey="Messinger D" first="Diethelm" last="Messinger">Diethelm Messinger</name><affiliation wicri:level="3"><inist:fA14 i1="05"><s1>IST</s1><s2>Mannheim</s2><s3>DEU</s3><sZ>5 aut.</sZ></inist:fA14><country>Allemagne</country><placeName><region type="land" nuts="1">Bade-Wurtemberg</region><region type="district" nuts="2">District de Karlsruhe</region><settlement type="city">Mannheim</settlement></placeName></affiliation></author><author><name sortKey="Hadziyannis, Stephanos J" sort="Hadziyannis, Stephanos J" uniqKey="Hadziyannis S" first="Stephanos J." last="Hadziyannis">Stephanos J. Hadziyannis</name><affiliation wicri:level="3"><inist:fA14 i1="06"><s1>Henry Dunant Hospital</s1><s2>Athens</s2><s3>GRC</s3><sZ>6 aut.</sZ></inist:fA14><country>Grèce</country><placeName><settlement type="city">Athènes</settlement><region nuts="2" type="region">Attique (région)</region></placeName></affiliation></author><author><name sortKey="Marcellin, Patrick" sort="Marcellin, Patrick" uniqKey="Marcellin P" first="Patrick" last="Marcellin">Patrick Marcellin</name><affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Service d'Hepatologie and Centre de Recherches Biologiques Bichat Beaujon (Inserm CRB3), Hôpital Beaujon</s1><s2>Clichy</s2><s3>FRA</s3><sZ>7 aut.</sZ></inist:fA14><country>France</country><wicri:noRegion>Clichy</wicri:noRegion><wicri:noRegion>Hôpital Beaujon</wicri:noRegion><wicri:noRegion>Clichy</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">10-0133480</idno><date when="2010">2010</date><idno type="stanalyst">PASCAL 10-0133480 INIST</idno><idno type="RBID">Pascal:10-0133480</idno><idno type="wicri:Area/PascalFrancis/Corpus">002823</idno><idno type="wicri:Area/PascalFrancis/Curation">003763</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">002455</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">002455</idno><idno type="wicri:doubleKey">0270-9139:2010:Bruno S:efficacy:and:safety</idno><idno type="wicri:Area/Main/Merge">007F23</idno><idno type="wicri:Area/Main/Curation">007905</idno><idno type="wicri:Area/Main/Exploration">007905</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Efficacy and Safety of Peginterferon Alfa-2a (40KD) Plus Ribavirin in Hepatitis C Patients with Advanced Fibrosis and Cirrhosis</title><author><name sortKey="Bruno, Savino" sort="Bruno, Savino" uniqKey="Bruno S" first="Savino" last="Bruno">Savino Bruno</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>AO Fatebenefratelli e Oftalmico</s1><s2>Milan</s2><s3>ITA</s3><sZ>1 aut.</sZ></inist:fA14><country>Italie</country><placeName><settlement type="city">Milan</settlement><region nuts="2">Lombardie</region></placeName></affiliation></author><author><name sortKey="Shiffman, Mitchell L" sort="Shiffman, Mitchell L" uniqKey="Shiffman M" first="Mitchell L." last="Shiffman">Mitchell L. Shiffman</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Virginia Commonwealth University Medical Center</s1><s2>Blacksburg, VA</s2><s3>USA</s3><sZ>2 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Virginia Commonwealth University Medical Center</wicri:noRegion></affiliation></author><author><name sortKey="Roberts, Stuart K" sort="Roberts, Stuart K" uniqKey="Roberts S" first="Stuart K." last="Roberts">Stuart K. Roberts</name><affiliation wicri:level="3"><inist:fA14 i1="03"><s1>The Alfred Hospital</s1><s2>Melbourne</s2><s3>AUS</s3><sZ>3 aut.</sZ></inist:fA14><country>Australie</country><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Gane, Edward J" sort="Gane, Edward J" uniqKey="Gane E" first="Edward J." last="Gane">Edward J. Gane</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Auckland Clinical Studies</s1><s2>Auckland</s2><s3>NZL</s3><sZ>4 aut.</sZ></inist:fA14><country>Nouvelle-Zélande</country><wicri:noRegion>Auckland Clinical Studies</wicri:noRegion></affiliation></author><author><name sortKey="Messinger, Diethelm" sort="Messinger, Diethelm" uniqKey="Messinger D" first="Diethelm" last="Messinger">Diethelm Messinger</name><affiliation wicri:level="3"><inist:fA14 i1="05"><s1>IST</s1><s2>Mannheim</s2><s3>DEU</s3><sZ>5 aut.</sZ></inist:fA14><country>Allemagne</country><placeName><region type="land" nuts="1">Bade-Wurtemberg</region><region type="district" nuts="2">District de Karlsruhe</region><settlement type="city">Mannheim</settlement></placeName></affiliation></author><author><name sortKey="Hadziyannis, Stephanos J" sort="Hadziyannis, Stephanos J" uniqKey="Hadziyannis S" first="Stephanos J." last="Hadziyannis">Stephanos J. Hadziyannis</name><affiliation wicri:level="3"><inist:fA14 i1="06"><s1>Henry Dunant Hospital</s1><s2>Athens</s2><s3>GRC</s3><sZ>6 aut.</sZ></inist:fA14><country>Grèce</country><placeName><settlement type="city">Athènes</settlement><region nuts="2" type="region">Attique (région)</region></placeName></affiliation></author><author><name sortKey="Marcellin, Patrick" sort="Marcellin, Patrick" uniqKey="Marcellin P" first="Patrick" last="Marcellin">Patrick Marcellin</name><affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Service d'Hepatologie and Centre de Recherches Biologiques Bichat Beaujon (Inserm CRB3), Hôpital Beaujon</s1><s2>Clichy</s2><s3>FRA</s3><sZ>7 aut.</sZ></inist:fA14><country>France</country><wicri:noRegion>Clichy</wicri:noRegion><wicri:noRegion>Hôpital Beaujon</wicri:noRegion><wicri:noRegion>Clichy</wicri:noRegion></affiliation></author></analytic><series><title level="j" type="main">Hepatology : (Baltimore, Md.)</title><title level="j" type="abbreviated">Hepatology : (Baltim. Md.)</title><idno type="ISSN">0270-9139</idno><imprint><date when="2010">2010</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Hepatology : (Baltimore, Md.)</title><title level="j" type="abbreviated">Hepatology : (Baltim. Md.)</title><idno type="ISSN">0270-9139</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antineoplastic agent</term><term>Antiviral</term><term>Cirrhosis</term><term>Fibrosis</term><term>Gastroenterology</term><term>Human</term><term>Immunomodulator</term><term>Peginterferon alfa-2a</term><term>Ribavirin</term><term>Toxicity</term><term>Viral hepatitis C</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Cirrhose</term><term>Peginterféron alfa-2a</term><term>Toxicité</term><term>Ribavirine</term><term>Hépatite virale C</term><term>Homme</term><term>Fibrose</term><term>Gastroentérologie</term><term>Immunomodulateur</term><term>Antiviral</term><term>Anticancéreux</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The objective of this study is to determine the efficacy and safety of peginterferon alfa-2a (40KD)/ribavirin in patients with advanced fibrosis. Data from 341 genotype 1/4 patients (99 with bridging fibrosis/cirrhosis) treated for 48 weeks and 1547 genotype 2/3 patients (380 with bridging fibrosis/cirrhosis) treated for 16 or 24 weeks enrolled in three randomized international studies were analyzed. Sustained virological response (SVR) rates decreased progressively from 60% in genotype 1/4 patients without advanced fibrosis to 51% in those with bridging fibrosis and 33% in those with cirrhosis (trend test P = 0.0028); and from 76% to 61% and 57%, respectively, in genotype 2/3 patients treated for 24 weeks (trend test P < 0.0001). Irrespective of genotype, patients without advanced fibrosis were more likely to have an earlier response to treatment that was associated with higher SVR rates and lower relapse rates during untreated follow-up. Among patients with or without a diagnosis of advanced fibrosis, rates of SVR and relapse were similar for patients with similar responses in the first 12 weeks. Conclusion: Compared with patients with less severe disease, SVR rates are significantly lower in patients with advanced fibrosis. However, irrespective of genotype and degree of fibrosis, the time to become hepatitis C virus (HCV) RNA undetectable was the strongest predictor of SVR.</div></front></TEI><affiliations><list><country><li>Allemagne</li><li>Australie</li><li>France</li><li>Grèce</li><li>Italie</li><li>Nouvelle-Zélande</li><li>États-Unis</li></country><region><li>Attique (région)</li><li>Bade-Wurtemberg</li><li>District de Karlsruhe</li><li>Lombardie</li><li>Victoria (État)</li></region><settlement><li>Athènes</li><li>Mannheim</li><li>Melbourne</li><li>Milan</li></settlement></list><tree><country name="Italie"><region name="Lombardie"><name sortKey="Bruno, Savino" sort="Bruno, Savino" uniqKey="Bruno S" first="Savino" last="Bruno">Savino Bruno</name></region></country><country name="États-Unis"><noRegion><name sortKey="Shiffman, Mitchell L" sort="Shiffman, Mitchell L" uniqKey="Shiffman M" first="Mitchell L." last="Shiffman">Mitchell L. Shiffman</name></noRegion></country><country name="Australie"><region name="Victoria (État)"><name sortKey="Roberts, Stuart K" sort="Roberts, Stuart K" uniqKey="Roberts S" first="Stuart K." last="Roberts">Stuart K. Roberts</name></region></country><country name="Nouvelle-Zélande"><noRegion><name sortKey="Gane, Edward J" sort="Gane, Edward J" uniqKey="Gane E" first="Edward J." last="Gane">Edward J. Gane</name></noRegion></country><country name="Allemagne"><region name="Bade-Wurtemberg"><name sortKey="Messinger, Diethelm" sort="Messinger, Diethelm" uniqKey="Messinger D" first="Diethelm" last="Messinger">Diethelm Messinger</name></region></country><country name="Grèce"><region name="Attique (région)"><name sortKey="Hadziyannis, Stephanos J" sort="Hadziyannis, Stephanos J" uniqKey="Hadziyannis S" first="Stephanos J." last="Hadziyannis">Stephanos J. Hadziyannis</name></region></country><country name="France"><noRegion><name sortKey="Marcellin, Patrick" sort="Marcellin, Patrick" uniqKey="Marcellin P" first="Patrick" last="Marcellin">Patrick Marcellin</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 007905 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 007905 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= Pascal:10-0133480
|texte= Efficacy and Safety of Peginterferon Alfa-2a (40KD) Plus Ribavirin in Hepatitis C Patients with Advanced Fibrosis and Cirrhosis
}}
| This area was generated with Dilib version V0.6.33. |  |